Case Report: Brain metastasis from cervical cancer treated with multimodal therapy
- 1Zhongshan Hospital of Traditional Chinese Medicine Affiliated to Guangzhou University of Chinese Medicine
- 2Zhongshan Hospital of Traditional Chinese Medicine
Abstract
Brain metastasis from cervical cancer is exceptionally rare, occurring in 0.4%–2.3% of cases and portending a dismal prognosis, with a median survival of approximately 6.2 months after the diagnosis of brain metastasis. Here we report a 51-year-old woman initially diagnosed with stage IVB papillary squamous cell carcinoma of the cervix. Initial therapy combining albumin-bound paclitaxel, cisplatin, and the anti-PD-1 antibody tislelizumab, followed by pelvic radiotherapy, achieved durable disease control. Nineteen months after diagnosis, she developed memory decline and headache; brain MRI disclosed large, radiologically presumed metastases in the right frontal-basal ganglia and left occipital lobe. As the patient declined surgery, she received bevacizumab, paclitaxel, and the bispecific PD-1/CTLA-4 antibody iparomlimab/tuvonralimab (Ipa-tuv), together with focal fractionated VMAT (3900 cGy in 13 fractions) to the brain lesions. The dominant lesion decreased from 66 × 54 × 58 mm to 45 × 54 × 49 mm, and neurological symptoms resolved. Because of financial constraints, Ipa-tuv was later discontinued and she was maintained on bevacizumab plus chemotherapy. At the last two imaging time points, an increase in perilesional edema was noted; no clear size-based progression was demonstrated, although progression, radiation-related change, and treatment-related necrosis could not be excluded. At the last radiological assessment (January 25, 2026), the overall survival was approximately 34 months from the initial diagnosis and approximately 15 months since the diagnosis of radiologically presumed brain metastases. This case describes the observed response to a multimodal treatment strategy, although the contribution of any single component cannot be determined, and further prospective trials are warranted.
Related
- Case Report: Multimodal treatment of cervical intramedullary spinal cord metastasis from gastric adenocarcinoma
- Cervical squamous cell carcinoma manifesting as a solitary metastasis to the skeletal muscle of the scapular region accompanied by invasion of the adjacent bone while on PD-1 inhibitor maintenance therapy: a case report.
- Multimodal Management of Isolated Pulmonary Metastasis From Choroidal Melanoma: A Case Report
- Multimodal Large Language Models for Prognostic Prediction in Cervical Cancer Treated with Definitive Chemoradiotherapy: An Exploratory Study of Systematic Multimodal Data Integration.
- Multimodal radiomics based on dynamic contrast-enhanced ultrasound for predicting cervical lymph node metastasis in papillary thyroid carcinoma with Hashimoto’s thyroiditis
BibTeX
@article{liu2026case,
title = {{Case Report: Brain metastasis from cervical cancer treated with multimodal therapy}},
author = {Juntong Liu and Yunxin Wen and Yuyi Peng and Huatang Zhang and Cantu Fang and Jincheng Meng},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1929899},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1929899/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Case Report: Brain metastasis from cervical cancer treated with multimodal therapy
AU - Juntong Liu
AU - Yunxin Wen
AU - Yuyi Peng
AU - Huatang Zhang
AU - Cantu Fang
AU - Jincheng Meng
PY - 2026
DA - 2026/10/28
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1929899
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1929899/full
AB - Brain metastasis from cervical cancer is exceptionally rare, occurring in 0.4%–2.3% of cases and portending a dismal prognosis, with a median survival of approximately 6.2 months after the diagnosis of brain metastasis. Here we report a 51-year-old woman initially diagnosed with stage IVB papillary squamous cell carcinoma of the cervix. Initial therapy combining albumin-bound paclitaxel, cisplatin, and the anti-PD-1 antibody tislelizumab, followed by pelvic radiotherapy, achieved durable disease control. Nineteen months after diagnosis, she developed memory decline and headache; brain MRI disclosed large, radiologically presumed metastases in the right frontal-basal ganglia and left occipital lobe. As the patient declined surgery, she received bevacizumab, paclitaxel, and the bispecific PD-1/CTLA-4 antibody iparomlimab/tuvonralimab (Ipa-tuv), together with focal fractionated VMAT (3900 cGy in 13 fractions) to the brain lesions. The dominant lesion decreased from 66 × 54 × 58 mm to 45 × 54 × 49 mm, and neurological symptoms resolved. Because of financial constraints, Ipa-tuv was later discontinued and she was maintained on bevacizumab plus chemotherapy. At the last two imaging time points, an increase in perilesional edema was noted; no clear size-based progression was demonstrated, although progression, radiation-related change, and treatment-related necrosis could not be excluded. At the last radiological assessment (January 25, 2026), the overall survival was approximately 34 months from the initial diagnosis and approximately 15 months since the diagnosis of radiologically presumed brain metastases. This case describes the observed response to a multimodal treatment strategy, although the contribution of any single component cannot be determined, and further prospective trials are warranted.
SN - 2234-943X
ER -